NeuroOne Medical Technologies Corporation
NMTC | NASDAQ
$1.38
+$0.08 (+6.15%)
At close: Sep 22, 2026, 4:00 PM ET
$1.39
+$0.01 (+0.72%)
After-hours:
Sep 22, 2026, 7:43 PM ET
Company Profile
NeuroOne Medical Technologies Corporation functions as a specialized medical technology enterprise. Its core mission involves the invention and market deployment of sophisticated thin-film electrode systems. These systems are crafted for diverse neurophysiological applications, such as the continuous recording of electroencephalograms (cEEG) and stereoelectroencephalograms (sEEG), as well as therapeutic interventions including spinal cord stimulation, brain stimulation, and ablation procedures. The technology aims to assist individuals afflicted by conditions like epilepsy, Parkinson's disease, dystonia, essential tremors, persistent pain arising from unsuccessful back surgeries, and a variety of other neurological disorders. Furthermore, the company has forged a crucial partnership with RBC Medical Innovations to engineer a radio frequency ablation generator. This generator is designed to integrate seamlessly with NeuroOne's unique dual-function electrode, allowing for both the precise monitoring of brain electrical activity and the targeted ablation of brain tissue using a singular instrument. The corporate headquarters are situated in Eden Prairie, Minnesota.
Key Executives
| Name | Position |
|---|---|
| David A. Rosa | President, Chief Executive Officer & Director |
| Christopher R. Volker | Chief Financial Officer |
| Steven Mertens | Chief Technology Officer |
| David J. Wambeke | Chief Business Officer |
| Emily Johns | Chief Administrative Officer & General Counsel |
| Hijaz Haris | Vice President of Marketing |
| Mark Christianson | Co-Founder, Business Development Director & Medical Sales Liaison |
| Parag G. Patil | Chief Medical Advisor |
| Ronald W. McClurg | Senior Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 28, 2026 | 4 | Filing |
| Aug 28, 2026 | 4 | Filing |
| Aug 28, 2026 | 4 | Filing |
| Aug 28, 2026 | 4 | Filing |
| Aug 28, 2026 | 4 | Filing |
| Aug 27, 2026 | 8-K | Current Report |
| Aug 13, 2026 | 10-Q | Quarterly Report |
| Aug 13, 2026 | 8-K | Current Report |
| Jul 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 14, 2026 | 3 | Filing |
NeuroOne Medical Technologies Corporation
| Country | United States |
| IPO Date | Mar 14, 2018 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 18 |
| CEO | David A. Rosa |
Contact Details
7599 Anagram Drive Eden Prairie,
Minnesota 55344 United States
Stock Details
| Ticker Symbol | NMTC |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001500198 |
| CUSIP Number | 64130M308 |
| ISIN Number | US64130M3088 |
| SIC Code | 3841 |
Add to Watchlist
Select watchlists to add or remove NMTC